Skip to main content
SpringerLink
Log in

Acute myeloid leukemia: highlights from ASH 2015

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Summary

Despite of the progress achieved in recent years for acute myeloid leukemia (AML) treatment, there is still a need for improvement, both for younger and elderly patients. This review covers studies for AML presented at the ASH 2015 annual meeting. The presentations selected offer a glimpse of the future of AML treatment. Also in AML insights into the molecular pathogenesis can be translated into clinical practice where a major step has been set with the first positive trial with respect to overall survival for the tyrosine kinase inhibitor midostaurin. Also for older patients, unfit for chemotherapy, therapy options are increasingly available. Individualized therapies will require both new trial designs and new approaches for patient assessment and clinical decision making.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Dissecting genetic and phenotypic heterogeneity to map molecular phylogenies and deliver personalized outcome and treatment predictions in AML. Blood. 2015;126:803.

    Google Scholar 

  2. Stone RM, Mandrekar S, Sanford BL, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P‑controlled bouble-blind trial (CALGB 10603/RATIFY [Alliance]). Blood. 2015;126:6.

    Article  Google Scholar 

  3. Schlenk R, Döhner K, Salih H, et al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose Cytarabine (NCT01477606). Blood. 2015;126:322.

    Google Scholar 

  4. Uy GL, Mandrekar S, Laumann K, et al. Addition of sorafenib to chemotherapy improves the overall survival of older adults with FLT3-ITD mutated acute myeloid leukemia (AML) (Alliance C11001). Blood. 2015;126:319.

    Article  Google Scholar 

  5. Stein EM, DiNardo C, Altman JK, et al. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1/2 trial. Blood. 2015;126:323.

    Google Scholar 

  6. Foran JM, Sun Z, Claxton DF, et al. North American leukemia, intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and Decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age ≥60 years): a trial of the ECOG-ACRIN cancer research group (E2906). Blood. 2015;126:217.

    Google Scholar 

  7. Thomas X, De Botton S, Chevret S, et al. Clofarabine-based consolidation improves relapse-free survival of younger adults with non-favorable acute myeloid leukemia (AML) in first remission: results of the randomized ALFA-0702/Clara study (NCT 00932412). Blood. 2015;126:218.

    Google Scholar 

  8. Russell NH, Hills RK, Freeman S, et al. A comparison of 1 or 2 courses of high dose cytarabine as consolidation in younger patients with AML: first results of the UK NCRI AML17 trial. Blood. 2015;126:221.

    Google Scholar 

  9. Röllig C, Kramer M, Gabrecht M, et al. Randomized comparison of intermediate-dose cytarabine plus mitoxantrone (IMA) versus standard-dose cytarabine plus daunorubicin (DA) for induction therapy in AML patients 〉60 years. results from the SAL 60+ trial. Blood. 2015;126:222.

    Article  Google Scholar 

  10. Ades L, Thomas X, Guerci-Bresler A, et al. Is arsenic trioxide (ATO) required in the treatment of standard risk newly diagnosed APL? Analysis of a randomized trial (APL 2006) by the french belgian swiss APL group. Blood. 2015;126:451.

    Google Scholar 

  11. Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in acute myeloid leukemia with 〉30 % bone marrow blasts and 〈15 G/L white blood cell count: results from the Austrian Azacitidine Registry of the AGMT Study Group versus randomized controlled phase III clinical trial data. Blood. 2015;126:2515.

    Google Scholar 

  12. Seymour JF, Silverman LR, Döhner H, et al. The safety and tolerability of azacitidine (AZA) are comparable in patients with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS). Blood. 2015;126:3754.

    Google Scholar 

  13. DiNardo C, Pollyea D, Pratz K, et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Blood. 2015;126:327.

    Article  Google Scholar 

  14. Garcia-Manero G, Berdeja JD, Komrokji RS, et al. A randomized, placebo-controlled, phase II study of pracinostat in combination with azacitidine (AZA) in patients with previously untreated myelodysplastic syndrome (MDS). Blood. 2015;126:911.

    Google Scholar 

  15. Fathi AT, Erba HP, Lancet JE, et al. SGN-CD33A plus hypomethylating agents: a novel, well-tolerated regimen with high remission rate in frontline unfit AML. Blood. 2015;126:454.

    Article  Google Scholar 

  16. Daver N, Kantarjian HM, Garcia-Manero G, et al. Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Blood. 2015;126:461.

    Google Scholar 

  17. Kantarjian HM, Roboz GJ, Kropf PL, et al. Comparison of efficacy and safety results in 103 treatment-naïve acute myeloid leukemia (TN-AML) patients not candidates for intensive chemotherapy using 5‑day and 10-day regimens of guadecitabine (SGI-110), a novel hypomethylating agent (HMA). Blood. 2015;126:458.

    Google Scholar 

  18. Voso MT, Leone G, Piciocchi A, et al. Feasibililty of azacitidine as bridge to allogeneic stem cell transplantation in patients with higher-risk MDS or low-blast count AML: results of the BMT-AZA multicenter prospective study. Blood. 2015;126:66.

    Google Scholar 

  19. Scott BL, Pasquini MC, Logan B, et al. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): blood and marrow transplant clinical trials network (BMT CTN) 0901. Blood. 2015;126:LBA-8.

    Google Scholar 

  20. Ferguson P, Hills RK, Grech A, et al. An operational definition of primary refractory acute myeloid leukaemia which allows early identification of patients for whom allogeneic stem cell transplantation represents the only curative therapy. Blood. 2015;126:559.

    Article  Google Scholar 

  21. Lee SC, Dvinge H, Kim E, et al. Therapeutic targeting of spliceosomal mutant myeloid leukemias through modulation of splicing catalysis. Blood. 2015;126:4.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 3rd Medical Department for Hematology and Oncology, Hanusch Krankenhaus, Heinrich Collinstraße 30, 1140, Vienna, Austria

    Michael Pfeilstöcker MD, MBA

Authors
  1. Michael Pfeilstöcker MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Pfeilstöcker MD, MBA.

Ethics declarations

Conflict of interest

M. Pfeilstöcker has received speaker honoraria and consultancy fees from Celgene and Novartis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pfeilstöcker, M. Acute myeloid leukemia: highlights from ASH 2015. memo 9, 116–119 (2016). https://doi.org/10.1007/s12254-016-0275-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-016-0275-3

Keywords

Search

Navigation